Research *CME

January 20, 2022

Journal Club Discusses JAK Inhibitors (CME)

Join us for another Psound Bytes Journal Club episode discussing noteworthy publications in psoriatic disease. In this episode, we discuss recent research and advancements with JAK inhibitors with Dr. Andrew Blauvelt, President, Oregon Medical Research Center in Portland, OR.

Publications:

Chimalakonda A, Burke J, Cheng L, et al. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors. Dermatol Ther (Heidelb). 2021;11(5):1763-1776. doi:10.1007/s13555-021-00596-8

Krueger JG, McInnes IB, Blauvelt A. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis. J Am Acad Dermatol. 2022;86(1):148-157. doi:10.1016/j.jaad.2021.06.869

Abduelmula A, Gooderham MJ. TYK2 inhibition: changing the treatment landscape for psoriasis? [published online ahead of print, 2021 Nov 23]. Expert Rev Clin Immunol. 2021;1-3. doi:10.1080/1744666X.2022.2008240

McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study [published correction appears in RMD Open. 2021 Nov;7(3):]. RMD Open. 2021;7(3):e001838. doi:10.1136/rmdopen-2021-001838

Wohlrab J, Stintzing D, Schultz L, Jügelt K, Schroeder OH. Influence of Janus Kinase Inhibitors on the Neuronal Activity as a Proof-of-Concept Model for Itch [published online ahead of print, 2021 Sep 16]. Skin Pharmacol Physiol. 2021;10.1159/000519669. doi:10.1159/000519669

Słuczanowska-Głąbowska S, Ziegler-Krawczyk A, Szumilas K, Pawlik A. Role of Janus Kinase Inhibitors in Therapy of Psoriasis. J Clin Med. 2021;10(19):4307. Published 2021 Sep 22. doi:10.3390/jcm10194307

Barnard, C. FDA approves upadacitinib for selected psoriatic arthritis patients. medwireNews. 2021 Dec 20. Accessed 2022 Jan 19. https://www.medwirenews.com/rheumatology/fda-approval/19968574

This program is supported by educational grants from AbbVie, Amgen, Janssen and UCB.

Share
Related Items

Stay in the Know.

Expert tips, can’t-miss events and the latest news, straight to your inbox.

National Health Council Standards of ExcellenceCharity Navigator

Copyright © 1996-2021 National Psoriasis Foundation/USA


Duplication, rebroadcast, republication or other use of content appearing on this website is prohibited without written permission of the National Psoriasis Foundation (NPF).


NPF does not endorse or accept any responsibility for the content of external websites.


NPF does not endorse any specific treatments or medications for psoriasis and psoriatic arthritis.

We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.